Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2020-21 Influenza Season.

IF 33.7 1区 医学 Q1 Medicine Mmwr Recommendations and Reports Pub Date : 2020-08-21 DOI:10.15585/mmwr.rr6908a1
Lisa A Grohskopf, Elif Alyanak, Karen R Broder, Lenee H Blanton, Alicia M Fry, Daniel B Jernigan, Robert L Atmar
{"title":"Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2020-21 Influenza Season.","authors":"Lisa A Grohskopf,&nbsp;Elif Alyanak,&nbsp;Karen R Broder,&nbsp;Lenee H Blanton,&nbsp;Alicia M Fry,&nbsp;Daniel B Jernigan,&nbsp;Robert L Atmar","doi":"10.15585/mmwr.rr6908a1","DOIUrl":null,"url":null,"abstract":"<p><p>This report updates the 2019-20 recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines in the United States (MMWR Recomm Rep 2019;68[No. RR-3]). Routine annual influenza vaccination is recommended for all persons aged ≥6 months who do not have contraindications. For each recipient, a licensed and age-appropriate vaccine should be used. Inactivated influenza vaccines (IIVs), recombinant influenza vaccine (RIV4), and live attenuated influenza vaccine (LAIV4) are expected to be available. Most influenza vaccines available for the 2020-21 season will be quadrivalent, with the exception of MF59-adjuvanted IIV, which is expected to be available in both quadrivalent and trivalent formulations.Updates to the recommendations described in this report reflect discussions during public meetings of ACIP held on October 23, 2019; February 26, 2020; and June 24, 2020. Primary updates to this report include the following two items. First, the composition of 2020-21 U.S. influenza vaccines includes updates to the influenza A(H1N1)pdm09, influenza A(H3N2), and influenza B/Victoria lineage components. Second, recent licensures of two new influenza vaccines, Fluzone High-Dose Quadrivalent and Fluad Quadrivalent, are discussed. Both new vaccines are licensed for persons aged ≥65 years. Additional changes include updated discussion of contraindications and precautions to influenza vaccination and the accompanying Table, updated discussion concerning use of LAIV4 in the setting of influenza antiviral medication use, and updated recommendations concerning vaccination of persons with egg allergy who receive either cell culture-based IIV4 (ccIIV4) or RIV4.The 2020-21 influenza season will coincide with the continued or recurrent circulation of SARS-CoV-2 (the novel coronavirus associated with coronavirus disease 2019 [COVID-19]). Influenza vaccination of persons aged ≥6 months to reduce prevalence of illness caused by influenza will reduce symptoms that might be confused with those of COVID-19. Prevention of and reduction in the severity of influenza illness and reduction of outpatient illnesses, hospitalizations, and intensive care unit admissions through influenza vaccination also could alleviate stress on the U.S. health care system. Guidance for vaccine planning during the pandemic is available at https://www.cdc.gov/vaccines/pandemic-guidance/index.html.This report focuses on recommendations for the use of vaccines for the prevention and control of seasonal influenza during the 2020-21 season in the United States. A brief summary of the recommendations and a link to the most recent Background Document containing additional information are available at https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html. These recommendations apply to U.S.-licensed influenza vaccines used within Food and Drug Administration (FDA)-licensed indications. Updates and other information are available from CDC's influenza website (https://www.cdc.gov/flu). Vaccination and health care providers should check this site periodically for additional information.</p>","PeriodicalId":51328,"journal":{"name":"Mmwr Recommendations and Reports","volume":"69 8","pages":"1-24"},"PeriodicalIF":33.7000,"publicationDate":"2020-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7439976/pdf/","citationCount":"226","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mmwr Recommendations and Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15585/mmwr.rr6908a1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 226

Abstract

This report updates the 2019-20 recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines in the United States (MMWR Recomm Rep 2019;68[No. RR-3]). Routine annual influenza vaccination is recommended for all persons aged ≥6 months who do not have contraindications. For each recipient, a licensed and age-appropriate vaccine should be used. Inactivated influenza vaccines (IIVs), recombinant influenza vaccine (RIV4), and live attenuated influenza vaccine (LAIV4) are expected to be available. Most influenza vaccines available for the 2020-21 season will be quadrivalent, with the exception of MF59-adjuvanted IIV, which is expected to be available in both quadrivalent and trivalent formulations.Updates to the recommendations described in this report reflect discussions during public meetings of ACIP held on October 23, 2019; February 26, 2020; and June 24, 2020. Primary updates to this report include the following two items. First, the composition of 2020-21 U.S. influenza vaccines includes updates to the influenza A(H1N1)pdm09, influenza A(H3N2), and influenza B/Victoria lineage components. Second, recent licensures of two new influenza vaccines, Fluzone High-Dose Quadrivalent and Fluad Quadrivalent, are discussed. Both new vaccines are licensed for persons aged ≥65 years. Additional changes include updated discussion of contraindications and precautions to influenza vaccination and the accompanying Table, updated discussion concerning use of LAIV4 in the setting of influenza antiviral medication use, and updated recommendations concerning vaccination of persons with egg allergy who receive either cell culture-based IIV4 (ccIIV4) or RIV4.The 2020-21 influenza season will coincide with the continued or recurrent circulation of SARS-CoV-2 (the novel coronavirus associated with coronavirus disease 2019 [COVID-19]). Influenza vaccination of persons aged ≥6 months to reduce prevalence of illness caused by influenza will reduce symptoms that might be confused with those of COVID-19. Prevention of and reduction in the severity of influenza illness and reduction of outpatient illnesses, hospitalizations, and intensive care unit admissions through influenza vaccination also could alleviate stress on the U.S. health care system. Guidance for vaccine planning during the pandemic is available at https://www.cdc.gov/vaccines/pandemic-guidance/index.html.This report focuses on recommendations for the use of vaccines for the prevention and control of seasonal influenza during the 2020-21 season in the United States. A brief summary of the recommendations and a link to the most recent Background Document containing additional information are available at https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html. These recommendations apply to U.S.-licensed influenza vaccines used within Food and Drug Administration (FDA)-licensed indications. Updates and other information are available from CDC's influenza website (https://www.cdc.gov/flu). Vaccination and health care providers should check this site periodically for additional information.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
用疫苗预防和控制季节性流感:免疫实践咨询委员会的建议-美国,2020-21流感季节。
本报告更新了免疫实践咨询委员会(ACIP)关于在美国使用季节性流感疫苗的2019- 2020年建议(MMWR建议Rep 2019;68)。RR-3])。建议所有年龄≥6个月且无禁忌症的人每年常规接种流感疫苗。对于每个接受者,应使用许可的和适合年龄的疫苗。灭活疫苗(IIVs)、重组流感疫苗(RIV4)和减毒活疫苗(LAIV4)预计将上市。2020-21流感季可获得的大多数流感疫苗将是四价疫苗,但mf59佐剂iv疫苗除外,预计将有四价和三价两种剂型。本报告中所述建议的更新反映了2019年10月23日举行的ACIP公开会议上的讨论;2020年2月26日;2020年6月24日。该报告的主要更新包括以下两个项目。首先,2020-21年美国流感疫苗的成分包括甲型H1N1流感(pdm09)、甲型流感(H3N2)和乙型流感/维多利亚流感谱系成分的更新。其次,讨论了最近两种新的流感疫苗——高剂量四价流感疫苗和四价流感疫苗的许可。这两种新疫苗均获批用于年龄≥65岁的人群。其他的变化包括对流感疫苗禁忌症和预防措施的更新讨论以及随附的表格,关于在流感抗病毒药物使用背景下使用lai4的更新讨论,以及关于接受基于细胞培养的IIV4 (ccIIV4)或RIV4的鸡蛋过敏者接种疫苗的更新建议。2020-21年流感季节将与SARS-CoV-2(与2019冠状病毒病相关的新型冠状病毒[COVID-19])的持续或反复传播相吻合。为降低由流感引起的疾病的流行,为≥6个月的人接种流感疫苗,将减少可能与COVID-19相混淆的症状。通过流感疫苗预防和降低流感疾病的严重程度,减少门诊疾病、住院和重症监护病房的入院,也可以减轻美国卫生保健系统的压力。大流行期间疫苗规划指南可在https://www.cdc.gov/vaccines/pandemic-guidance/index.html.This获得。报告重点介绍了美国在2020-21年季节使用疫苗预防和控制季节性流感的建议。建议的简要摘要和包含更多信息的最新背景文件的链接可在https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html上获得。这些建议适用于在美国食品和药物管理局(FDA)许可适应症中使用的美国许可的流感疫苗。最新情况和其他信息可从疾病预防控制中心的流感网站(https://www.cdc.gov/flu)获得。疫苗接种和卫生保健提供者应定期查看此网站以获取更多信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Mmwr Recommendations and Reports
Mmwr Recommendations and Reports PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-
CiteScore
36.00
自引率
0.00%
发文量
3
期刊介绍: The MMWR series of publications is published by the Office of Science, Centers for Disease Control and Prevention (CDC), U.S. The MMWR Recommendations and Reports contain in-depth articles that relay policy statements for prevention and treatment in all areas in the CDC’s scope of responsibility (e.g., recommendations from the Advisory Committee on Immunization Practices).
期刊最新文献
CDC Program Evaluation Framework, 2024. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-25 Influenza Season. U.S. Selected Practice Recommendations for Contraceptive Use, 2024. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1